AbbVie Inc. (ABBV) Stock: Surges as $10.9 Billion Apogee Deal Expands Immunology Pipeline

TLDR AbbVie closes $10.9B Apogee deal and expands its immunology treatment pipeline. ABBV stock rises as Apogee adds key programs targeting dermatitis and asthma. Zumilokibart becomes a major new asset in AbbVie’s expanding immunology pipeline. AbbVie expects near-term EPS dilution before the deal turns accretive in 2032. AbbVie keeps 2026 EPS guidance unchanged after completing [...]

The post AbbVie Inc. (ABBV) Stock: Surges as $10.9 Billion Apogee Deal Expands Immunology Pipeline appeared first on Blockonomi.